CANCRO FEGATO NON OPERABILE. NIVOLUMAB PIU’ IPILIMUMAB > LENVATINIB OR SORAFENIB IN PRIMA LINEA. UN TRIAL RANDOMIZZATO DA “THE LANCET” (FREE!)
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial Thomas Yau et al. Summary Background Patients with unresectable hepatocellular carcinoma have a poor prognosis, and treatments with long-term benefits are needed. We report results from the preplanned interim analysis of the CheckMate 9DW…

